Life-threatening complications of Crohns disease and ulcerative colitis: A systematic analysis of admissions to an ICU during 18 years;Lebensbedrohliche Komplikationen von Morbus Crohn und Colitis ulcerosa

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 14, 2010, Pages 668-674

  Huber, W ^a   Herrmann, G ^a   Schuster, T ^b   Phillip, V ^a   Saugel, B ^a   Schultheiss, C ^a   Hoellthaler, J ^a   Gaa, J ^c   Hartel, M ^a   Schmid, R M ^a   Reindl, W ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Institut für Medizinische Epidemiologie und Statistik   (Germany)

^c Institut für Röntgendiagnostik   (Germany)

Author keywords

Complications; Crohns disease; Inflammatory bowel diseases; Intensive care; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB;

ARTICLE; CANDIDA; CROHN DISEASE; DISEASE COURSE; DISEASE EXACERBATION; ELECTROLYTE DISTURBANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTESTINE PERFORATION; LENGTH OF STAY; MULTIPLE ORGAN FAILURE; PNEUMOCYSTIS PNEUMONIA; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS PNEUMONIA;

ADULT; AGED; CAUSE OF DEATH; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GERMANY; HOSPITAL MORTALITY; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950553975     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1251915     Document Type: Article

References (33)

1. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J P., Cosnes J. Predictors of Crohns disease. Gastroenterology 2006 130 650-656
2. Beigel F, Jürgens M, Filik L et al. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohns disease. Inflamm Bowel Dis 2009 15 1240-1244
3. Bokemeyer B. CED-Behandlung in Deutschland. Gastroenterologe 2007 6 447-455
4. Cottone M, Magliocco A, Rosselli M et al. Mortality in patients with Crohns disease. Scand J Gastroenterol 1996 31 372-375
5. DHaens G, Baert F, Van A G., Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease. Lancet 2008 371 660-667
6. Davoli M, Prantera C, Berto E, Scribano M L., D?Ippoliti D. Mortality among patients with ulcerative colitis: Rome 19701989. Eur J Epidemiol 1997 13 189-194
7. Ekbom A, Helmick C, Zack M, Adami H O. The epidemiology of inflammatory bowel disease. Gastroentereology 1991 100 350-358
8. Farrokhyar F, Swarbrick E T., Grace R H., Hellier M D., Gent A E., Irvine E J. Low mortality in ulcerative colitis and Crohn?s disease in three regional centers in England. Am J Gastroenterol 2001 96 501-507
9. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999 94 1551-1555
10. Gaffney P R., Doyle C T., Gaffney A, Hogan J, Hayes D P., Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995 90 220-223
11. Gyde S N., Prior P, Allan R N., Stevens A, Jewell D P., Truelove S C., Lofberg R, Brostrom O, Hellers G. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988 29 206-217
12. Hanauer S B., Sandborn W J., Rutgeerts P, Fedorak R N., Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial. Gastroenterology 2006 130 323-333
13. Herrlinger K, Wittig B, Stange E F. Chronisch entzündliche Darmerkrankungen: Pathophysiologie und Therapie. Internist 2009 50 1229-1246
14. Jess T, Winther K V., Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn?s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002 122 1808-1814
15. Kethu S R. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006 40 467-475
16. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992 103 1444-1451
17. Moody G A., Mayberry J F. Life insurance and inflammatory bowel disease: is there discrimination against patients? Int J Colorectal Dis 1996 11 276-278
18. Palli D, Trallori G, Saieva C, Tarantino O, Edili E, DAlbasio G, Pacini F, Masala G. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease. Gut 1998 42 175-179
19. Persson P G., Bernell O, Leijonmarck C E., Farahmand B Y., Hellers G, Ahlbom A. Survival and cause-specific mortality in inflammatory bowel diseas. Gastroenterolgoy 1996 110 1339-1345
20. Rahier J F., Ben-Horin S, Chowers Y, et al., on behalf of the European Crohns and Colitis Organisation on behalf of the European Crohns and Colitis Organisation (ECCO). European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009 3 47-91
21. Reindl W, Schmid R M., Huber W. Cyclosporin A treatment of steroid-refractory ulcerative colitis during pregnancy. Gut 2007 56 1019
22. Ricart E, Panaccione R, Loftus E V Jr et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease. Inflamm Bowel Dis 2004 10 207-214
23. Sandborn W J., Colombel J F., Enns R et al. Natalizumab induction and maintenance therapy for Crohns disease. N Engl J Med 2005 353 1912-1925
24. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohns disease. Gut 2009 58 492-500
25. Schölmerich J. Therapie bei chronisch-entzündlichen Darmerkrankungen. Praxis (Bern 1994) 2007 96 337-343
26. Schölmerich J. Balancing the risks and benefits of prolonged use of infliximab. Gut 2009 58 477-478
27. Schreiber S, Rutgeerts P, Fedorak R N. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohns disease. Gastroenterology 2005 129 807-818
28. Thayu M, Markowitz J E., Mamula P, Russo P A., Muinos W I., Baldassano R N. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005 40 220-222
29. Timmer A. Epidemiologie der CED. In: Hoffmann JC, Kroesen AJ, Klump B Chronisch entzündliche Darmerkrankungen: Das CED-Handbuch für Klinik und Praxis. Stuttgart Thieme 2004 8-19
30. Toruner M, Loftus E V Jr, Harmsen W S., Zinsmeister A R., Orenstein R, Sandborn W J., Colombel J F., Egan L J. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 929-936
31. Viscido A, Bagnardi V, Sturniolo G C., Annese V, Frieri G, DArienzo A, Papi C, Riegler G, Corrao G, Caprilli R. GISC: Italian Group for the Study of the Colon and Rectum. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig Liver Dis 2001 33 686-692
32. Weterman I T., Biemond I, Pena A S. Mortality and causes of death in Crohn?s disease. Gut 1990 31 1387-1390
33. Winther K V., Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colits: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003 125 1576-1582